)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Ligand Pharmaceuticals
Ligand Pharmaceuticals (LGND) investor relations material
Ligand Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Achieved strong financial performance in 2025, with full-year adjusted EPS up 42% to $8.13, exceeding original guidance by over 30%, and royalty revenue growing 48% year-over-year, driven by key products including FILSPARI, Ohtuvayre, CAPVAXIVE, QARZIBA, and Zelsuvmi.
Strategic initiatives included systematic portfolio management, expansion of the business development team, and special transactions such as the Pelthos and Channel Therapeutics merger.
Portfolio includes 12 key commercial royalty assets generating ~$200M in cash flow and a deep pipeline supporting future growth.
Maintained over $1 billion in deployable capital, positioning for continued expansion and disciplined investments.
Financial highlights
Full-year 2025 GAAP revenue reached $268 million, up from $167 million in 2024; core revenue (excluding Pelthos gain) was $240 million, up 43% year-over-year.
Royalty revenue grew to $161 million, a 48% increase year-over-year; Q4 total revenue was $59.7 million, up 39% from the prior year.
Core adjusted diluted EPS rose to $8.13, up 42% year-over-year; Q4 adjusted net income was $42.7 million or $2.02 per share.
Ended 2025 with $734 million in cash equivalents and short-term investments, and over $1 billion in deployable capital including equity holdings and credit facility.
Operating income improved to $41 million from a loss of $22.6 million in 2024.
Outlook and guidance
2026 guidance reaffirmed: adjusted EPS of $8–$9 per share, royalty revenue of $200–$225 million (32% growth at midpoint), total revenue of $245–$285 million.
Royalty growth in 2026 expected to be driven by FILSPARI, Ohtuvayre, CAPVAXIVE, and ZELSUVMI.
Five-year outlook projects a 23% CAGR in royalty receipts from 2025–2030, with visibility to over $13.50 adjusted EPS by 2030.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ligand Pharmaceuticals earnings date
Q1 20267 May, 2026
Ligand Pharmaceuticals
Next Ligand Pharmaceuticals earnings date
Q1 20267 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that focuses on developing and licensing innovative technologies and drug discovery platforms to pharmaceutical companies. Ligand’s business model centers around partnerships, where it provides proprietary drug development technologies such as its OmniAb antibody discovery platform and Captisol drug formulation technology. These technologies are used to support the development of therapies across a wide range of therapeutic areas, including oncology, infectious diseases, and autoimmune disorders. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage